The BEZ235 drug was applied to mice before damaging the DNA with radiation, which blocked the defences of a protein called PI3K and stopped tumours from growing.
Lead author of the project Dr Pier Paolo Scaglioni, an assistant professor of internal medicine at UT Southwestern, claimed that it is the first treatment of its kind that targets non-small cell lung cancers that harbour K-RAS mutations.
These mutations play a key role in activating the networks which regulate cell growth.
He said: "These early results suggest that the drug-radiation combination might be an effective therapy in lung cancer patients."
The study was published in the October issue of Cancer Research.
A recent study carried out at the College of Health Professions and Social Work indicated that the cancer treatment of Asian people in the US is at risk because several cultures with different health issues are listed in the same demographic.